menu search

cingulate to host cns key opinion leader panel in new york city

Expert Analysis of Cingulate, its Phase 3 ADHD Adult Data, Anxiety, and PTR™ Drug Delivery Platform Innovations KANSAS CITY, Kan., Oct. 17, 2023 (GL...

October 17, 2023, 6:22 pm

cingulate inc. to present at the ld micro main event xvi

Presentation on Wednesday, October 4th at 02:30 PM PT Kansas City, Kansas--(Newsfile Corp. - September 21, 2023) - ...

September 21, 2023, 11:23 am

cingulate announces detailed trial results from phase 3 adult efficacy and safety trial of ctx-1301 (dexmethylphenidate) for adhd

CTx-1301 Demonstrated Clinically Meaningful Improvements in Permanent Product Measure of Performance (PERMP) and Clinical Global Impression Scale (CGI...

September 11, 2023, 10:00 am

cingulate to participate in the healthcare virtual conference part ii presented by maxim group and hosted by m-vest

KANSAS CITY, Kan., June 14, 2023 (GLOBE NEWSWIRE) — cingulate Inc. (NASDAQ: CING), a biopharmaceutica...

June 14, 2023, 7:45 pm

cingulate to participate in the healthcare virtual conference part ii presented by maxim group and hosted by m-vest

KANSAS CITY, Kan., June 14, 2023 (GLOBE NEWSWIRE) -- cingulate Inc. (NASDAQ: CING), a biopharmaceutical...

June 14, 2023, 3:45 pm

cingulate to present at 13th annual ld micro invitational

KANSAS CITY, Kan., May 25, 2023 (GLOBE NEWSWIRE) — cingulate Inc. (NASDAQ: CING), a biopharmaceutical...

May 25, 2023, 7:55 pm

cingulate to present at 13th annual ld micro invitational

KANSAS CITY, Kan., May 25, 2023 (GLOBE NEWSWIRE) -- cingulate Inc. (NASDAQ: CING), a biopharmaceutical ...

May 25, 2023, 3:55 pm

Cingulate, indegene to participate in benzinga all live access event

KANSAS CITY, Kan., May 12, 2023 (GLOBE NEWSWIRE) — cingulate Inc. (NASDAQ: CING), a biopharmaceutical...

May 12, 2023, 7:45 pm

cingulate announces successful transfer of ctx-1301 (dexmethylphenidate) proprietary ptr™ manufacturing processes to societal cdmo

Scalable Supply of CTx-1301 Ready to be Produced with cingulate on Track to Meet Previously Announced C...

May 3, 2023, 10:45 am

Why is cingulate (cing) stock up 72% today?

cingulate (NASDAQ: CING ) stock is on the rise Friday after releasing positive data concerning its ADHD...

February 24, 2023, 7:47 am

cingulate initiates phase 3 study of lead asset ctx-1301, designed as a true entire active-day treatment for adhd

Trial Results Expected 1H 2023 Company to Host Investor and Business Development Meetings Adjacent to Upcoming J.P. Morgan Healthcare Conference in Sa...

January 4, 2023, 11:45 am

cingulate to participate in benzinga all live access event

KANSAS CITY, Kan., Nov. 30, 2022 (GLOBE NEWSWIRE) — cingulate Inc. (NASDAQ: CING), a biopharmaceutica...

November 30, 2022, 8:00 pm

cingulate inc. to present at investor summit group's q4 conference

Kansas City, Kansas--(Newsfile Corp. - November 3, 2022) - cingulate Inc. (NASDAQ: CING), a biopharmace...

November 3, 2022, 7:00 am

cingulate to present at h.c. wainwright global investment conference

KANSAS CITY, Kan., May 18, 2022 (GLOBE NEWSWIRE) -- cingulate Inc. (NASDAQ: CING), a clinical-stage bio...

May 18, 2022, 5:20 pm

cingulate outlines plan for pivotal attention deficit/hyperactivity disorder studies

cingulate Inc CING plans to initiate Phase 3 studies for CTx-1301 for Attention Deficit/Hyperactivit...

February 8, 2022, 12:20 pm

cingulate outlines plan for pivotal attention deficit/hyperactivity disorder studies

cingulate Inc CING plans to initiate Phase 3 studies for CTx-1301 for Attention Deficit/Hyperactivit...

February 8, 2022, 12:20 pm

cingulate outlines plan for pivotal attention deficit/hyperactivity disorder studies

cingulate Inc CING plans to initiate Phase 3 studies for CTx-1301 for Attention Deficit/Hyperactivit...

February 8, 2022, 12:20 pm


Search within

Pages Search Results: